Zydus Life Science has been trading around its all-time high for last few weeks, although there was a small consolidation phase after a strong rally. Stock has regained its lost strength and trying to cross 1030-1040 levels.
Company is expected to report its Q4 earnings on May 24. We need to watch if it can beat or miss the estimates to see further up move in the price.
Based on its current price, it is traded at a PE of 34.7 which is lower than industry average PE of 41.4If it can break 1030 levels, technically it can show a good up-move if the market and earnings supports.
Please do your own research before taking a position in the stock. We are not SEBI registered.
Zydus life science delivered a fantastic results. We will see on the next session if the stock performs well, or if the profit booking is going to happen.